Haematologists welcome funding for cutting-edge blood cancer diagnostic test

MedTech & Diagnostics News: In celebrating International Pathology Day earlier this week, haematologists have welcomed the new Medicare Benefits Schedule (MBS) funding for blood cancers. Approved by the federal government earlier this year and now officially funded, this precision diagnostic testing, known as the haematological malignancy gene panel test, is set to transform the diagnosis and treatment of blood cancers, including leukaemia, lymphoma, and myeloma.

Peter MacCallum Cancer Centre’s Haematologist, Associate Professor Piers Blombery, who played a pivotal role in securing funding for this critical diagnostic tool, collaborated closely with The Royal College of Pathologists of Australasia and haematologists from across the country to make this funding a reality.

“This is such a massive leap forward for improving the diagnosis and treatment of patients with blood cancer in Australia – it is difficult to overstate the importance,” said Associate Professor Blombery. “This testing is vital and will help us determine the diagnosis, prognosis, and management of a patient presenting with a clinically suspected haematological malignancy of myeloid or lymphoid origin.”

The haematological malignancy gene panel test is a sophisticated diagnostic tool that allows haematologists to develop personalized treatment plans for patients based on their genetic profile. It identifies mutations that have approved targeted therapies, offering valuable insights into how the cancer is likely to respond to specific treatments.

“When a particular mutation is identified, we can choose a targeted therapy that is more likely to be effective for that specific genetic alteration,” explained Professor Blombery. “Instead of a one-size-fits-all approach, treatments are tailored to the individual’s genetic profile, which can lead to more effective treatment with fewer side effects.”

As treatment progresses, repeated gene panel tests can be conducted to monitor changes in the genetic profile of the cancer. This ensures that the treatment strategy remains effective over time, adapting as needed to the patient’s evolving condition.

The expanded genetic testing will be conducted through Peter Mac’s Pathology Department and the Wilson Centre for Blood Cancer Genomics.

Additionally, a range of other changes to genetic testing through Medicare were implemented on November 1st. Among these, 85,000 people each year are expected to benefit from new Medicare rebates for couples to determine their combined risk of having a child born with cystic fibrosis (CF), spinal muscular atrophy (SMA), or fragile X syndrome (FXS). Furthermore, Medicare rebates for genetic testing to diagnose mitochondrial disease will become available, offering a less invasive and more effective method for diagnosing this challenging condition.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.